Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009–2010
Neelima Mishra, Jai Prakash Narayan Singh, Bina Srivastava, Usha Arora, Naman K Shah, SK Ghosh, RM Bhatt, SK Sharma, MK Das, Ashwani Kumar, Anupkumar R Anvikar, Kamlesh Kaitholia, Ruchi Gupta, GS Sonal, AC Dhariwal & Neena Valecha
Volume 90, Number 12, December 2012, 895-904
Table 3. Predictors of treatment failure among patients in studies conducted under India’s National Antimalarial Drug Resistance Monitoring System, India, 2009–2010
|Predictor||RRa (95% CI)|
|Artesunate dose (mg/kg)b|
|3.0 to < 3.5||2.45 (0.58–10.3)|
|< 3.0||6.10 (1.04–35.8)|
|< 5||4.46 (1.35–14.7)|
|Parasitaemia (asexual parasites/μl)|
|≥ 5 000||0.47 (0.22–1.00)|
|< 5 000||–|
|Fever at enrolment (≥ 37.5 °C)|
RR, relative risk; CI, confidence interval.
a Relative risk for the failure of treatment of Plasmodium falciparum infection with a combination of artesunate and sulfadoxine-pyrimethamine, as estimated in a multivariate analysis.
b The dose given per day.